BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 2 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,460,650 | +31.8% | 245,000 | -14.0% | 0.05% | +31.4% |
| Q2 2023 | $4,902,000 | +12.7% | 285,000 | 0.0% | 0.04% | +16.7% |
| Q1 2023 | $4,349,303 | +493.1% | 285,000 | +196.1% | 0.03% | +500.0% |
| Q4 2022 | $733,345 | -23.0% | 96,244 | +0.5% | 0.01% | -28.6% |
| Q3 2022 | $952,000 | -73.9% | 95,775 | -76.2% | 0.01% | -76.7% |
| Q2 2022 | $3,649,000 | -10.5% | 401,912 | 0.0% | 0.03% | +7.1% |
| Q1 2022 | $4,079,000 | -39.2% | 401,912 | 0.0% | 0.03% | -34.9% |
| Q4 2021 | $6,704,000 | -68.6% | 401,912 | -11.7% | 0.04% | -70.3% |
| Q3 2021 | $21,338,000 | -23.1% | 455,285 | 0.0% | 0.14% | -23.7% |
| Q2 2021 | $27,754,000 | – | 455,285 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $373,797,000 | 67.28% |
| Darwin Global Management, Ltd. | 2,090,149 | $128,753,000 | 25.21% |
| Affinity Asset Advisors, LLC | 577,500 | $35,574,000 | 12.08% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $1,913,356,000 | 9.64% |
| Perceptive Advisors | 7,756,928 | $477,827,000 | 6.04% |
| Opaleye Management Inc. | 583,767 | $35,960,000 | 5.28% |
| MIZUHO MARKETS AMERICAS LLC | 171,923 | $10,590,000 | 4.93% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $1,639,853,000 | 4.88% |
| Fernwood Investment Management, LLC | 151,085 | $9,307,000 | 3.42% |
| HHLR ADVISORS, LTD. | 5,362,014 | $330,300,000 | 3.26% |